Polymorphous low-grade neuroepithelial tumor of the young with FGFR3-TACC3 fusion mimicking high-grade glioma: case report and series of high-grade correlates.
FGFR fusion
PLNTY
glioblastoma
glioma molecular drivers
high-grade glioma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
10
2023
accepted:
02
11
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
epublish
Résumé
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a recently described entity that can mimic high-grade glioma (HGG) in histologic and molecular features; however, factors predicting aggressive behavior in these tumors are unclear. We present an indolent neuroepithelial neoplasm in a 59-year-old female with imaging initially suggestive of HGG, and a series of adult patients with HGG harboring FGFR3-TACC3 fusions are also presented for comparison. Pathology in the case patient revealed low-grade cytomorphology, microcalcifications, unusual neovascularization, and a low proliferation index. The lesion was diffusely CD34+ and harbored an FGFR3-TACC3 fusion and TERT promoter mutation. A diagnosis of PLNTY was therefore favored and the patient was observed with no progression at 15-month follow-up. In patients with HGG with FGFR3-TACC3 fusions, molecular findings included IDH-wildtype status, absence of 1p19q codeletion, CDKN2A loss, TERT promoter mutations and lack of MGMT promoter methylation. These patients demonstrated a median 15-month overall survival and a 6-month progression-free survival. PLNTY is a rare low-grade entity that can display characteristics of HGG, particularly in adults. Presence of FGFR3-TACC3 fusions and other high-grade features should raise concern for a more malignant precursor lesion when a diagnosis of PLNTY is considered.
Sections du résumé
Background
UNASSIGNED
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a recently described entity that can mimic high-grade glioma (HGG) in histologic and molecular features; however, factors predicting aggressive behavior in these tumors are unclear.
Methods
UNASSIGNED
We present an indolent neuroepithelial neoplasm in a 59-year-old female with imaging initially suggestive of HGG, and a series of adult patients with HGG harboring FGFR3-TACC3 fusions are also presented for comparison.
Results
UNASSIGNED
Pathology in the case patient revealed low-grade cytomorphology, microcalcifications, unusual neovascularization, and a low proliferation index. The lesion was diffusely CD34+ and harbored an FGFR3-TACC3 fusion and TERT promoter mutation. A diagnosis of PLNTY was therefore favored and the patient was observed with no progression at 15-month follow-up. In patients with HGG with FGFR3-TACC3 fusions, molecular findings included IDH-wildtype status, absence of 1p19q codeletion, CDKN2A loss, TERT promoter mutations and lack of MGMT promoter methylation. These patients demonstrated a median 15-month overall survival and a 6-month progression-free survival.
Conclusion
UNASSIGNED
PLNTY is a rare low-grade entity that can display characteristics of HGG, particularly in adults. Presence of FGFR3-TACC3 fusions and other high-grade features should raise concern for a more malignant precursor lesion when a diagnosis of PLNTY is considered.
Identifiants
pubmed: 38074682
doi: 10.3389/fonc.2023.1307591
pmc: PMC10698862
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1307591Informations de copyright
Copyright © 2023 Golub, Lynch, Pan, Liechty, Slocum, Bale, Pisapia and Juthani.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Epilepsy Behav. 2017 Feb;67:91-97
pubmed: 28110204
BMC Neurol. 2020 Apr 6;20(1):123
pubmed: 32252664
Neuropathology. 2018 Oct;38(5):557-560
pubmed: 30051533
Acta Neuropathol. 2018 Aug;136(2):273-291
pubmed: 29564591
Oncotarget. 2018 Sep 28;9(76):34306-34319
pubmed: 30344944
Acta Neuropathol. 2021 Jan;141(1):123-125
pubmed: 33226472
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
World Neurosurg. 2019 Dec;132:347-355
pubmed: 31520766
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Eur J Immunol. 1995 Jun;25(6):1508-16
pubmed: 7542195
Neuro Oncol. 2017 Sep 01;19(9):1206-1216
pubmed: 28379477
Acta Neurol Belg. 2020 Jun;120(3):729-732
pubmed: 31754999
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Rev Neurol. 2016 Dec;12(12):732-740
pubmed: 27857123
Epilepsia. 2013 Dec;54 Suppl 9:18-24
pubmed: 24328867
Science. 2012 Sep 7;337(6099):1231-5
pubmed: 22837387
J Cancer Res Clin Oncol. 2016 Jul;142(7):1581-9
pubmed: 27100354
Nat Commun. 2018 May 25;9(1):2087
pubmed: 29802247
Acta Neuropathol Commun. 2020 Feb 21;8(1):21
pubmed: 32085805
J Clin Invest. 2013 Feb;123(2):548-51
pubmed: 23298839
Clin Cancer Res. 2015 Jul 15;21(14):3307-17
pubmed: 25609060
World Neurosurg. 2019 Jul;127:47-51
pubmed: 30926558
Clin Cancer Res. 2019 Sep 15;25(18):5537-5547
pubmed: 31263031
Clin Cancer Res. 2019 Aug 15;25(16):4888-4897
pubmed: 31088831
Brain Pathol. 2018 Sep;28(5):674-683
pubmed: 28976058
J Child Neurol. 2015 Nov;30(13):1838-50
pubmed: 25873586
Brain Pathol. 2020 Jul;30(4):844-856
pubmed: 32307792
Neuroradiology. 2019 Nov;61(11):1327-1332
pubmed: 31396664
J Clin Invest. 2013 Feb;123(2):855-65
pubmed: 23298836
Acta Neuropathol. 2014 Jul;128(1):39-54
pubmed: 24858213
J Neuropathol Exp Neurol. 2019 Dec 1;78(12):1100-1111
pubmed: 31617914
Acta Neuropathol. 2017 Mar;133(3):417-429
pubmed: 27812792
Clin Neuropathol. 2018 Jul-Aug;37(4):178-181
pubmed: 29701169
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
J Clin Neurosci. 2017 Oct;44:158-163
pubmed: 28673671
AJNR Am J Neuroradiol. 2020 Apr;41(4):573-578
pubmed: 32217553
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neuropathology. 2023 Aug;43(4):319-325
pubmed: 36545913